PMID- 27111455
OWN - NLM
STAT- MEDLINE
DCOM- 20180209
LR  - 20180313
IS  - 1096-9101 (Electronic)
IS  - 0196-8092 (Linking)
VI  - 48
IP  - 7
DP  - 2016 Sep
TI  - The short-term effects of aflibercept on the size of choroidal neovascularization 
      lesion in treatment-resistant neovascular age-related macular degeneration as 
      determined by spectral-domain optical coherence tomography.
PG  - 668-77
LID - 10.1002/lsm.22531 [doi]
AB  - BACKGROUND AND OBJECTIVES: To evaluate the changes in the size of choroidal 
      neovascularization (CNV) lesion using spectral domain-optical coherence 
      tomography (SD-OCT) in patients with treatment-resistant neovascular age-related 
      macular degeneration (AMD) who were switched from ranibizumab to aflibercept. 
      MATERIALS AND METHODS: In this prospective case-series, 33 eyes of 30 patients 
      with treatment-resistant neovascular AMD were included. Treatment-resistant 
      neovascular AMD was defined as choriodal neovascularization secondary to AMD 
      determined by subretinal fluid and/or intraretinal fluid/cysts after more than 6 
      months of monthly ranibizumab therapy. Enrolled eyes were received intravitreal 
      aflibercept injections at weeks 0, 4, and 8. Maximum area of CNV lesion in the 
      cross-sectional area in the B-scan was measured using Heidelberg Eye Explorer 
      software. The same cross-sectional sections containing maximum area of CNV lesion 
      were used during the follow-up. CNV subtypes were determined based on fluorescein 
      angiography images prior to ranibizumab therapy. Main outcome measures were 
      changes in best-corrected visual acuity (BCVA), central subfield thickness (CST), 
      and area of CNV lesion. RESULTS: There were five classic (15%), seven minimally 
      classic (21%), and 21 occult subtypes of CNV (64%). Four weeks after the third 
      injection, BCVA improvement and reduction of the retinal thickness in nine 
      standard ETDRS subfields were significant (both P < 0.001). Regarding and 
      regardless of CNV subtypes, mean area of CNV lesion decreased significantly at 
      final visit. Overall, a dry macula was achieved in 21 eyes (64%) and 12 eyes 
      (36%) showed decreased or unchanged edema. CONCLUSIONS: Switching to aflibercept 
      seems to result in reduction of CNV lesion area in short-term follow-up of 
      patients with treatment-resistant neovascular AMD. Lasers Surg. Med. 48:668-677, 
      2016. (c) 2016 Wiley Periodicals, Inc.
CI  - (c) 2016 Wiley Periodicals, Inc.
FAU - Abri Aghdam, Kaveh
AU  - Abri Aghdam K
AD  - Department of Ophthalmology, University Eye Hospital, Hannover Medical School, 
      Hannover, Germany.
AD  - Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran 
      University of Medical Sciences, Tehran, Iran.
FAU - Seidensticker, Florian
AU  - Seidensticker F
AD  - Department of Ophthalmology, University Eye Hospital, Hannover Medical School, 
      Hannover, Germany.
FAU - Pielen, Amelie
AU  - Pielen A
AD  - Department of Ophthalmology, University Eye Hospital, Hannover Medical School, 
      Hannover, Germany.
FAU - Framme, Carsten
AU  - Framme C
AD  - Department of Ophthalmology, University Eye Hospital, Hannover Medical School, 
      Hannover, Germany.
FAU - Junker, Bernd
AU  - Junker B
AD  - Department of Ophthalmology, University Eye Hospital, Hannover Medical School, 
      Hannover, Germany.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160425
PL  - United States
TA  - Lasers Surg Med
JT  - Lasers in surgery and medicine
JID - 8007168
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 15C2VL427D (aflibercept)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Choroidal Neovascularization/diagnostic imaging/*drug therapy/pathology
MH  - Drug Administration Schedule
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Intravitreal Injections
MH  - Macular Degeneration/diagnostic imaging/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Receptors, Vascular Endothelial Growth Factor/*therapeutic use
MH  - Recombinant Fusion Proteins/*therapeutic use
MH  - Tomography, Optical Coherence/*methods
MH  - Treatment Outcome
OTO - NOTNLM
OT  - aflibercept
OT  - choroidal neovascularization
OT  - ranibizumab
OT  - spectral domain-optical coherence tomography
EDAT- 2016/04/26 06:00
MHDA- 2018/02/10 06:00
CRDT- 2016/04/26 06:00
PHST- 2016/04/04 00:00 [accepted]
PHST- 2016/04/26 06:00 [entrez]
PHST- 2016/04/26 06:00 [pubmed]
PHST- 2018/02/10 06:00 [medline]
AID - 10.1002/lsm.22531 [doi]
PST - ppublish
SO  - Lasers Surg Med. 2016 Sep;48(7):668-77. doi: 10.1002/lsm.22531. Epub 2016 Apr 25.